Last updated on July 2019

A Safety Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA


Brief description of study

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. Once 31 flares are reported the study will be completed.

Clinical Study Identifier: NCT03000439

Find a site near you

Start Over

Phoenix Children's Hospital

Phoenix, AZ United States
  Connect »

Children's Hospital Los Angeles

Los Angeles, CA United States
  Connect »

Primary Children's Hospital

Salt Lake City, UT United States
  Connect »

Centro Medico Privado de Reumatologia

San Miguel de Tucuman, Argentina
  Connect »

Bioreuma

Concepcion, Chile
  Connect »

SAHI CRCH MoH TR

Kazan, Russian Federation
  Connect »

FSAI NMRCCH MoH RF

Moscow, Russian Federation
  Connect »

FSBEI HE SPbSPMU MoH RF

Saint Petersburg, Russian Federation
  Connect »

SBHI SR RCCH No. 1

Yekaterinburg, Russian Federation
  Connect »

Emmed Research

Pretoria, South Africa
  Connect »

Panorama Medical Centre

Cape Town, South Africa
  Connect »